Liss M - Search Results

1

Genotype-Phenotype Features of Germline Variants of the TMEM127 Pheochromocytoma Susceptibility Gene: A 10-Year Update.

Armaiz-Pena G, Flores SK, Cheng ZM, Zhang X, Esquivel E, Poullard N, Vaidyanathan A, Liu Q, Michalek J, Santillan-Gomez AA, Liss M, Ahmadi S, Katselnik D, Maldonado E, Salgado SA, Jimenez C, Fishbein L, Hamidi O, Else T, Lechan R, Tischler AS, Benn DE, Dwight T, Clifton-Bligh R, Sanso G, Barontini M, Vincent D, Aronin N, Biondi B, Koops M, Bowhay-Carnes E, Gimenez-Roqueplo AP, Alvarez-Eslava A, Bruder JM, Kitano M, Burnichon N, Ding Y, Dahia PLM. Armaiz-Pena G, et al. Among authors: liss m. J Clin Endocrinol Metab. 2021 Jan 1;106(1):e350-e364. doi: 10.1210/clinem/dgaa741. J Clin Endocrinol Metab. 2021. PMID: 33051659 Free PMC article.

2

Chemoradiation Vs Radical Cystectomy for Muscle-invasive Bladder Cancer: A Propensity Score-weighted Comparative Analysis Using the National Cancer Database.

Kaushik D, Wang H, Michalek J, Liss MA, Liu Q, Jha RP, Svatek RS, Mansour AM. Kaushik D, et al. Among authors: liss ma. Urology. 2019 Nov;133:164-174. doi: 10.1016/j.urology.2019.05.062. Epub 2019 Aug 8. Urology. 2019. PMID: 31401220 Free PMC article.

3

Prevalence of pathogenic germline cancer risk variants in testicular cancer patients: Identifying high risk groups.

Ramamurthy C, Nassar AH, Abou Alaiwi S, Adib E, Akl EW, Yang S, Esplin ED, Liss MA, Tomlinson GE, Sonpavde GP. Ramamurthy C, et al. Urol Oncol. 2022 Mar;40(3):113.e9-113.e15. doi: 10.1016/j.urolonc.2021.12.014. Epub 2022 Jan 10. Urol Oncol. 2022. PMID: 35022142

4

Hereditary Cancer Gene Variants in Hispanic Men With a Personal or Family History of Prostate Cancer.

Ramamurthy C, Stutz EW, Goros M, Gelfond J, Johnson-Pais TL, Thompson IM Jr, Leach RJ, Liss MA. Ramamurthy C, et al. Among authors: liss ma. Clin Genitourin Cancer. 2022 Jun;20(3):237-243. doi: 10.1016/j.clgc.2022.01.008. Epub 2022 Jan 14. Clin Genitourin Cancer. 2022. PMID: 35260348

5

Prostate genetic score (PGS-33) is independently associated with risk of prostate cancer in the PLCO trial.

Liss MA, Xu J, Chen H, Kader AK. Liss MA, et al. Prostate. 2015 Sep;75(12):1322-8. doi: 10.1002/pros.23012. Epub 2015 May 15. Prostate. 2015. PMID: 25982801 Clinical Trial.

6

Does timing of targeted therapy for metastatic renal cell carcinoma impact treatment toxicity and surgical complications? A comparison of primary and adjuvant approaches.

Patel N, Woo J, Liss MA, Palazzi KL, Randall JM, Mehrazin R, Jabaj R, Mirheydar HS, Gillis K, Lee HJ, Patterson AL, Kane CJ, Millard F, Derweesh IH. Patel N, et al. Can J Urol. 2016 Apr;23(2):8227-33. Can J Urol. 2016. PMID: 27085828 Clinical Trial.

7

A comparative analysis of complications after robot-assisted radical prostatectomy for men aged ≤69 and ≥70 years.

Babaian KN, Skarecky D, Liss MA, Osann K, Lusch A, Ahlering TE. Babaian KN, et al. J Endourol. 2014 Dec;28(12):1435-8. doi: 10.1089/end.2014.0234. J Endourol. 2014. PMID: 25211698

8

17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort.

Lin DW, Zheng Y, McKenney JK, Brown MD, Lu R, Crager M, Boyer H, Tretiakova M, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Kolb S, Liss M, Morgan TM, Thompson IM, Wagner AA, Tsiatis A, Pingitore A, Nelson PS, Newcomb LF. Lin DW, et al. Among authors: liss m. J Clin Oncol. 2020 May 10;38(14):1549-1557. doi: 10.1200/JCO.19.02267. Epub 2020 Mar 4. J Clin Oncol. 2020. PMID: 32130059 Free PMC article.

9

Impact of facility type and volume on survival in patients with metastatic renal cell carcinoma.

Dursun F, Elshabrawy A, Wang H, Oelsen J, Liss M, Kaushik D, Ramamurthy C, Rodriguez R, Mansour AM. Dursun F, et al. Among authors: liss m. Can J Urol. 2021 Oct;28(5):10806-10816. Can J Urol. 2021. PMID: 34657653

10

Histological variants of non-muscle invasive bladder cancer: Survival outcomes of radical cystectomy vs. bladder preservation therapy.

Dursun F, Elshabrawy A, Wang H, Wu S, Liss MA, Kaushik D, Grosser D, Svatek RS, Mansour AM. Dursun F, et al. Among authors: liss ma. Urol Oncol. 2022 Jun;40(6):275.e1-275.e10. doi: 10.1016/j.urolonc.2022.02.004. Epub 2022 Mar 27. Urol Oncol. 2022. PMID: 35351370

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

304 results

Search Page